Bullish case
$225 to $250
More likely if New BD sustains low to mid single-digit revenue growth, expands margins through BD Excellence, uses Waters proceeds for debt reduction and buybacks, and avoids major product or litigation setbacks.
Becton, Dickinson and Company research snapshot
BDX AI Stock Analysis
BDX AI stock analysis currently reads Becton, Dickinson and Company as a focused medtech business after the Waters transaction, with durable hospital and procedure demand, improving fiscal 2026 EPS guidance, and meaningful debt reduction. The stock is not a certain bargain. At the July 8, 2026 data cutoff, BDX traded near $156.30 with verified market capitalization near $43.07 billion, while the technical setup still sat below the 200-day moving average and the investment case depended on post-separation execution, margins, free cash flow, and litigation control.
Current price
$156.30
Market cap
$43.07 billion
AI score
64 / 100
Rating
Focused medtech value reset, execution watch
Trend status
Short-term rebound above the 50-day average but below the 200-day average
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. BD has long public filings, investor releases, SEC reports, sell-side coverage, technical data feeds, and third-party financial databases.
- bias Check
- The main AI research risk is repeating the defensive medtech narrative while underweighting the February 2026 portfolio reset, leverage, tariff and grant pressure, litigation, and slower growth versus higher-quality device peers.
- ai Confidence
- High for reported FY2025 revenue, FY2025 EPS, Q2 FY2026 guidance, share count, market cap math, and balance sheet snapshots. Medium for forward valuation because New BD margins, portfolio mix, and procedure volumes can change after the Waters transaction.
- investment Certainty
- Medium. BD sells essential healthcare tools and has a long operating history, but investment certainty is limited by leverage, portfolio transition, below-200-day technical posture, and the need to prove faster organic growth.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BD sells essential medical supplies, medication management systems, interventional devices, and biopharma systems used by hospitals, labs, drugmakers, and clinicians. | High |
| Moat | The moat comes from regulated products, installed hospital workflows, manufacturing scale, clinical reliability, distribution reach, and switching costs in medication and procedure systems. | Medium-high |
| Management | Tom Polen led the BD 2025 portfolio reset and Waters transaction. The next test is whether New BD can convert focus into higher organic growth, margins, and cash returns. | Medium |
| Financial trend | FY2025 revenue was $21.84 billion and adjusted EPS was $14.40. Q2 FY2026 revenue from continuing operations was $4.714 billion, with updated adjusted EPS guidance of $12.52 to $12.72. | High |
| Valuation | At $156.30, the stock traded near 12.4x the midpoint of updated FY2026 adjusted EPS guidance, 1.78x book value, and 14.1x free cash flow per share. | Medium-high |
| Technical trend | BDX is above the 50-day moving average but below the 200-day moving average, so the rebound has not fully repaired the longer-term downtrend. | Medium |
| Risk level | Key risks include weak medtech growth, product quality issues, litigation, tariffs, research grant exposure, leverage, and execution risk after the Waters transaction. | Medium-high |
| AI confidence | Descriptive confidence is high because filings and data are rich. Return confidence is lower because multiple expansion depends on evidence that New BD can grow faster. | High data confidence |
| Investment certainty | Medium certainty. The page frames BDX as a scenario-based research candidate, not a buy or sell instruction. | Medium |
BDX AI stock forecast
BDX AI Stock Forecast Scenarios
The BDX AI stock forecast uses scenario math, not a precise prediction. Using the $12.62 midpoint of updated FY2026 adjusted EPS guidance and the July 8, 2026 price reference near $156.30, the audited three-year framework produced a bearish area near $107, a base area near $170, and a bullish area near $239 before dividends.
Base case
$160 to $180
More likely if adjusted EPS compounds near 4% and the market keeps BDX near a low-teens earnings multiple while waiting for proof of stronger organic growth.
Bearish case
$95 to $115
More likely if procedure demand slows, tariffs or grant cuts pressure margins, legal costs rise, debt reduction stalls, or investors assign a single-digit earnings multiple.
BDX AI technical analysis
BDX AI Technical Analysis
BDX AI technical analysis is mixed as of the July 8, 2026 data cutoff. The stock closed at $156.30 on July 7, 2026 and was above its 50-day moving average near $148, but it remained below a 200-day moving average near $175, keeping the broader trend unresolved.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $156.30 | StockAnalysis reported the July 7, 2026 close at $156.30. |
| Immediate support | $147 to $149 | The 20-day and 50-day moving average area is the first support cluster for the rebound. |
| Pivot support | $138.82 | Intellectia listed immediate pivot support near this level. A break would weaken the recovery setup. |
| Near resistance | $155 to $158 | BDX was testing this area at the July 7 close, so follow-through matters more than a single close. |
| Long-term resistance | $174 to $176 | StockAnalysis and Intellectia snapshots placed the 200-day moving average in this area. |
| Momentum | RSI roughly 59 to 63 | Momentum is firm but not deeply overbought based on StockAnalysis and Intellectia snapshots. |
| Volume | 20-day average near 2.77 million shares | Use this as a benchmark for judging whether a breakout has institutional participation. |
| Volatility | 52-week price change about -11% | The stock remains below year-ago levels despite the recent rebound. |
| Invalidation | Close below $147 | A decisive close below the moving average cluster would invalidate the near-term recovery framework. |
BDX AI trading strategy
BDX AI Trading Strategy Framework
The BDX AI trading strategy is a rules-based research framework, not personal advice. It combines technical confirmation, valuation discipline, and monitoring of New BD execution after the Waters transaction.
Trend-following setup
Watch for BDX to hold above the $147 to $149 moving average cluster, then reclaim the $174 to $176 200-day area on volume above the 20-day average.
A close back below $147, or a failed 200-day reclaim after earnings, should invalidate the trend-following setup.
Mean-reversion setup
If BDX pulls back toward support without a guidance cut, compare the price reaction with procedure demand, adjusted EPS guidance, debt reduction, and legal reserve updates.
Avoid averaging down if price weakness comes with lower organic growth, weaker free cash flow, or a new product quality issue.
Fundamental monitor
Track Q3 FY2026 revenue, adjusted EPS, segment growth, BD Excellence margin progress, cash, total debt, share count after buybacks, litigation, tariffs, and Waters transition milestones.
Do not treat a low forward P/E as a stop-loss rule. Position sizing should reflect leverage and medtech event risk.
Investment research summary
Four-master Research Compression
Business essence
BD turns medical device engineering, regulated manufacturing, drug delivery, medication management, interventional tools, and biopharma systems into repeat demand from hospitals, clinics, labs, and manufacturers.
Moat
The moat is built on reliability in clinical workflows, installed systems, regulatory approvals, product breadth, manufacturing scale, distribution relationships, and training costs. It is not immune from price pressure or product recalls.
Munger risk inversion
The thesis fails if New BD remains a slow grower, leverage limits flexibility, litigation absorbs cash, hospital customers push back on pricing, or product quality issues erode trust.
Management
Management completed the Biosciences and Diagnostic Solutions combination with Waters and used proceeds for debt retirement and buybacks. The key scorecard is simpler: organic growth, margin expansion, cash conversion, and disciplined capital allocation.
Industry trend
BD sits inside durable healthcare trends: aging populations, hospital automation, chronic disease, infection prevention, drug delivery, and minimally invasive procedures. The category is attractive, but growth is usually gradual rather than explosive.
Valuation and margin of safety
At about 12.4x updated FY2026 adjusted EPS guidance and a 7.1% free cash flow yield, BDX looks cheaper than many medtech peers. The margin of safety depends on whether the lower multiple reflects temporary transition risk or lasting low growth.
Source-backed data
BDX Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BDX closing price | $156.30 on July 7, 2026 | StockAnalysis quote snapshot | July 8, 2026 |
| Shares outstanding | 275.54 million | StockAnalysis statistics | July 8, 2026 |
| Market capitalization | $43.07 billion, verified as $156.30 x 275.54 million shares | financial_rigor.py market cap verification | July 8, 2026 |
| FY2025 revenue | $21.84 billion | BD FY2025 results release | July 8, 2026 |
| FY2025 net income | $1.68 billion, cross-checked against Macrotrends, AlphaQuery, and StockTitan | Macrotrends net income data | July 8, 2026 |
| FY2025 free cash flow | $2.7 billion | StockTitan financials | July 8, 2026 |
| Q2 FY2026 continuing operations | $4.714 billion revenue and $2.90 adjusted diluted EPS | BD Q2 FY2026 results release | July 8, 2026 |
| FY2026 adjusted EPS guidance | $12.52 to $12.72 | BD Q2 FY2026 results release | July 8, 2026 |
| Cash and total debt | $816 million cash and $17.28 billion total debt, MRQ | StockAnalysis statistics | July 8, 2026 |
| Waters transaction | BD completed the Biosciences and Diagnostic Solutions combination with Waters on February 9, 2026 | BD transaction completion release | July 8, 2026 |
| Valuation check | 12.39x midpoint FY2026 adjusted EPS, 1.78x book, 14.11x free cash flow per share, 2.69% dividend yield | financial_rigor.py valuation verification | July 8, 2026 |
| Technical snapshot | 50-day moving average near $148.03, 200-day moving average near $174.72, RSI near 59.52 | StockAnalysis technical statistics | July 8, 2026 |
Frequently Asked Questions
Read the ABT AI stock analysisView BKR AI stock forecastExplore MMM AI technical analysisCompare ideas in AI Stock PickerBuild a rules-based trading strategyScreen stocks with Pineify
This BDX AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, guidance changes, product news, legal updates, market moves, or macro conditions.